Clinical applications of cell-free fetal DNA from maternal plasma

Robbert J. P. Rijnders, Godelieve C. M. L. Christiaens, Bernadette Bossers, Jasper J. van der Smagt, C. Ellen van der Schoot, Masja de Haas

Research output: Contribution to journalArticleAcademicpeer-review

82 Citations (Scopus)

Abstract

OBJECTIVE: To describe our clinical experience with detection and analysis of cell-free fetal DNA derived from maternal plasma for prenatal sexing and fetal rhesus-D typing. METHODS: Real-time quantitative polymerase chain reactions (PCRs) of rhesus-D sequences and the SRY gene were validated and offered to patients with an enhanced risk for sex-linked fetal pathology and patients with rhesus-D antibodies. RESULTS: In die validation group, 72 samples were analyzed. Sensitivity of the rhesus-D real-time quantitative PCR in maternal plasma was 100% (95% confidence interval [CI]91.8%, 100%) and specificity was 96.6% (95% CI 82.2%,99.9%). Sensitivity of the SRY real-time quantitative PCR was 97.2% (95% CI 85.5%, 99.9%), and specificity was 100% (95% CI 88.1%, 100%). The technique was used successfully in a clinical setting in 24 women. Overall, invasive tests were avoided in 41.7% of these patients. CONCLUSION: Detection of cell-free fetal DNA from maternal plasma is a reliable technique that can substantially reduce invasive prenatal tests. (C) 2004 by The American College of Obstetricians and Gynecologists
Original languageEnglish
Pages (from-to)157-164
JournalObstetrics and Gynecology
Volume103
Issue number1
DOIs
Publication statusPublished - 2004

Cite this